U.S. COVID-19 Vaccine Product Information

COVID-19 vaccine recommendations have been updated as of February 28, 2024, to recommend adults ages 65 years and over receive an additional updated 2023-2024 COVID-19 vaccine dose. This page will be updated to align with the new recommendation. Learn more.

Find a suite of information and materials that are needed for each specific COVID-19 vaccine that cover administration, storage and handling, safety, and reporting.

Healthcare providers who administer the Moderna COVID-19 Vaccine (2023-2024 Formula) to individuals ages 6 months through 11 years should ensure the correct volume of the vaccine (0.25 mL) is withdrawn from the vial and administered to the recipient. Discard vial and excess volume after extracting a single dose.

For additional information, see FDA Announcement and Moderna COVID-19 Vaccine (2023-2024 Formula) Healthcare Provider Fact Sheet (fda.gov)

Prevaccination Screening Checklist

CDC is replacing the COVID-19 specific screening questionnaire these resources from Immunize.org that will help providers determine if a contraindication or precaution exists for all routinely recommended vaccines.

Janssen COVID-19 Vaccine is no longer available in the U.S. All remaining U.S. government stock of Janssen COVID-19 Vaccine expired May 7, 2023. Dispose of any remaining Janssen COVID-19 Vaccine in accordance with local, state, and federal regulations.

People ages 18 years and older who received 1 dose of Janssen COVID-19 Vaccine should be considered to have received a single-dose Janssen primary series.

People ages 18 years and older who received 1 or 2 Janssen COVID-19 Vaccine dose are recommended to receive 1 bivalent mRNA dose (Moderna or Pfizer-BioNTech) at least 2 months after completion of the previous dose.

See the Interim Clinical Considerations for additional information.